Literature DB >> 20476948

Methotrexate in rheumatoid arthritis.

Edwin Sl Chan1, Patricia Fernandez, Bruce N Cronstein.   

Abstract

After half a century of use, methotrexate continues to be a cornerstone in the therapy of rheumatoid arthritis. Renewed interest in the 1980s has brought new insights into the mechanisms of action and safety of the drug. The use of combination therapy in rheumatoid arthritis has not masked the value of methotrexate in a competitive market in any way. We review the pharmacodynamics and pharmacokinetics as applicable to its clinical use as an anti-inflammatory and disease-modifying agent here.

Entities:  

Year:  2007        PMID: 20476948     DOI: 10.1586/1744666X.3.1.27

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

1.  Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment.

Authors:  Der-Yuan Chen; Hui-Min Chih; Joung-Liang Lan; Hsin-Yueh Chang; Wei-Wen Chen; En-Pei Isabel Chiang
Journal:  BMC Med       Date:  2011-01-13       Impact factor: 8.775

2.  A novel dendritic mesoporous silica based sustained hydrogen sulfide donor for the alleviation of adjuvant-induced inflammation in rats.

Authors:  Yue Yu; Zhou Wang; Qinyan Yang; Qian Ding; Ran Wang; Zhaoyi Li; Yudong Fang; Junyi Liao; Wei Qi; Keyuan Chen; Meng Li; Yi Zhun Zhu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.